US OptionsDetailed Quotes
SPRB241220C1000
- 0.05
- -0.04-44.44%
15min DelayClose Dec 2 16:00 ET
0.05High0.05Low
0.05Open0.09Pre Close20 Volume926 Open Interest1.00Strike Price100.00Turnover309.27%IV91.96%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2926Delta0.9256Gamma10.96Leverage Ratio-0.0037Theta0.0001Rho3.21Eff Leverage0.0004Vega
Spruce Biosciences Stock Discussion
Sign in to post a comment
I will never undestend why this company is not investigated for manipulating the market on theirs own interest.
Let's go see why such investigation is neccessary and I hope Zebra will complain.
Spruce it is an Short-selling company which allways made negative reports or analysis in order to influence the market for theyr's own profit. Parallel with Short-selling they are also in real estate managment in New York where they loose b...
Let's go see why such investigation is neccessary and I hope Zebra will complain.
Spruce it is an Short-selling company which allways made negative reports or analysis in order to influence the market for theyr's own profit. Parallel with Short-selling they are also in real estate managment in New York where they loose b...
8
1
$Spruce Biosciences (SPRB.US)$
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
Spruce Biosciences (Nasdaq: SPRB) and HMNC Brain Health announced a strategic collaboration to develop a treatment for Major Depressive Disorder (MDD) using Spruce's tildacerfont and HMNC's Cortibon Genetic Selection Tool. The Phase 2 study is set to begin in Q4 2024. Should the study be successful, Spruce has the option to acquire e...
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
Spruce Biosciences (Nasdaq: SPRB) and HMNC Brain Health announced a strategic collaboration to develop a treatment for Major Depressive Disorder (MDD) using Spruce's tildacerfont and HMNC's Cortibon Genetic Selection Tool. The Phase 2 study is set to begin in Q4 2024. Should the study be successful, Spruce has the option to acquire e...
1
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
16
3
3
$Spruce Biosciences (SPRB.US)$ why did it drop from 5?
1
$Spruce Biosciences (SPRB.US)$ Stopped out at $0.82 from $0.84. shouldve sold the move up to $0.89 but i got greedy like always…
1
1
$Spruce Biosciences (SPRB.US)$ Looking for the exit already… hoping for bounce off $0.80’s could see a double bottom
1
$Spruce Biosciences (SPRB.US)$ Wow just saw a 60k bid pop up, looks like bottoms in
2
No comment yet
U got Fomo : They just released earnings and such during bad times in the market so they got pulled right under aswell. My mom use to work at Zebra before retiring. It’s an excellent business it’s just have to be sustained by a healthy economy